Navigation Links
HemoCue 201+ systems, Glucose

ProductsHemoCue 201+ systems, Glucose
Company HemoCue AB
Item HemoCue 201+ systems, Glucose
Features 
  • Method: Glucose dehydrogenase
  • Measurement range: Whole blood: 022.2 mmol/L (0400 mg/dL) Plasma Equivalent: 024.6 mmol/L (0444 mg/dL)
  • Laboratory accuracy and precision
  • Cuvette package flexibility
  • Quality Control
  • User friendliness and minimal maintenance
  • Data storage possibilities
  • PC software program
    • Description The HemoCue Glucose 201+ is the latest addition to the HemoCue glucose product range. Just as the earlier versions, the new system combines the precision and accuracy of a laboratory measurement with a quick turn around time and ease of use. The new pocket size analyser also stores results and QC results, together with date and time for up to 600 measurements. The stored data can be printed directly via an external printer or downloaded to a PC.

    The HemoCue systems consist of portable, handheld analyzers together with specially designed microcuvettes. The systems provide lab-quality results at the Point-of-Care. The systems are factory calibrated and measure at dual wavelengths to compensate for turbidity (except for the Urine albumin system, which measures turbidity). The correct volume of sample is drawn into the microcuvette by capillary action, where it is spontaneously mixed with the reagents in the cuvette cavity. No mixing of reagents, dispensing or pipetting is required.

    Info HemoCue AB
    Customer Service: (949) 859-2630
    Web site: http://www.hemocue.com

    Related medicine products :

    1. HemoCue 201 DM System, Hb
    2. HemoCue 201+ systems, Hb
    3. HemoCue 201 DM System, Glucose
    4. Glucose (Hexokinase)
    5. Glucose (Oxidase)
    6. Glucose Color Reagent
    7. Glucose Color Liquidplus Reagent
    8. Glucose UV Reagent
    9. Glucose UV Liquidplus
    10. Glucose Hexokinase Reagent Set
    11. Glucose Hexokinase Liquid
    ...ly invasive surgery is founded on superior medical...-Chip cameras, 1-Chip cameras, Light sources, Coup...nding needs., ,Superior resolution and color repr...meras, and are the benchmark by which all other me...
    ...ra System provides easy-to-use features, auto iris...amera head construction is based on Solos durable ...era System, International (GS9900-PAL) includes: ,...rd and video cables , (GS 9905) Camera head with 3...
    Provides a combination of concentrated cold / hot and compression for the elbow
    Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery.
    Medicine Products:
    (Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
    (Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
    (Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
    (Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
    Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
    ...eld at the Grampians Community Health Centre has m...r drugs //. Educating people about the adverse e...arried out by the GCH center. Problems related t...amilial and community factors all in some way happ...
    Drug - resistant microbes raise concerns
    ...rds and Primary Health Organisations, (PHOs), whic...en resolved //, with both parties reaching an agr... visits. An estimated 680,000 New Zealanders who ... 45 - 64 years, are expected to benefit from July ...
    ... reported that two tourists have contracted malari... that the recent outbreak //of malaria on the isla...ndustry. The tourists, a Canadian and an American...fter visiting Great Exuma. The Public Health Agen...
    Other Medicine News:Health News:Drug - resistant microbes raise concerns 2Health News:Outbreak of Malaria to Lead to Loss in Tourist Industry 2
    (Date:10/8/2008)...nolimumab Program to be Discontinued and Headcount...lts of its Portfolio Review; Zanolimumab Program ... Number of Employees... Genmab A/S (OMX: GEN),announced today that it is ...4(R)). In addition, as a result of a portfolio rev...
    (Date:10/8/2008)...inical program to evaluate TAXUS(R) Element(TM) Pl...ent, NATICK, Mass., Oct. 8 /PRNewswire-FirstCall/...day announced that it has completed enrollment in,...y,s third-generation,TAXUS(R) Element(TM) paclitax...ogram has enrolled nearly 1,500 patients at 100 U....
    (Date:10/8/2008)...France, Oct. 8 /- Vical Incorporated ...ical data and new nonclinical data,demonstrating t...adly,applicable in DNA- and protein-based infectio...nes. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,Se...resent the data today,Wednesday, October 8, at th...
    (Date:10/7/2008)...EGO, Oct. 7 /- Prometheus Laboratorie...announced findings from its,development of PROMETH...st,for irritable bowel syndrome (IBS). The finding... of particular biomarkers in blood samples,between...hese biomarkers,combined with a proprietary algor...
    Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Exclusion of common bile duct stones prior to gallstone operations 5081 1Exclusion of common bile duct stones prior to gallstone operations 5081 2UCLA Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine 5078 1UCLA Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine 5078 2Gamma interferon could aid fight against fungal infections 1046 1Gamma interferon could aid fight against fungal infections 1046 2Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 1Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 2Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 3Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 4Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 5
    ...One Month Study in Seventy Type 2 Diabetes Patient...hnologies Inc.,(TSX:CJB) today announced positiv...le-dose clinical study for the treatment of Type 2...(TM):Exendin-4.,Results from the study demonstra... tolerated and, when administered once-weekly at e...
    ...VERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inot... presentation of,positive Phase 2 clinical data de...potential for INO-1001 as a preventative agent for...ed in subjects,with acute ST-elevated myocardial i...coronary intervention. The presentation was,made i...
    Other Medicine Technology:PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 2PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 3PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 4Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4